BICYCLE THERAPEUTICS PLC Quarterly Interest Expense in USD from Q1 2021 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Bicycle Therapeutics Plc quarterly/annual Interest Expense history and growth rate from Q1 2021 to Q1 2024.
  • Bicycle Therapeutics Plc Interest Expense for the quarter ending March 31, 2024 was $821K, a 1.61% increase year-over-year.
  • Bicycle Therapeutics Plc Interest Expense for the twelve months ending March 31, 2024 was $3.28M, a 1.74% decline year-over-year.
  • Bicycle Therapeutics Plc annual Interest Expense for 2023 was $3.26M, a 2.42% decline from 2022.
  • Bicycle Therapeutics Plc annual Interest Expense for 2022 was $3.34M, a 12.1% increase from 2021.
  • Bicycle Therapeutics Plc annual Interest Expense for 2021 was $2.98M, a 553% increase from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $3.28M $821K +$13K +1.61% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $3.26M $820K -$6K -0.73% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $3.27M $814K -$3K -0.37% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $3.27M $821K -$62K -7.02% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $3.33M $808K -$10K -1.22% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $3.34M $826K +$6K +0.73% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 $3.34M $817K -$6K -0.73% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $3.34M $883K +$64K +7.81% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $3.28M $818K +$296K +56.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $2.98M $820K Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 $823K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $819K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $522K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.